$NVO bringing Kyinsu (once-weekly insulin icodec + semaglutide combo) to China — first-of-its-kind dosing convenience for diabetes patients. Also adding $30M capex to Tianjin plant for assembly capacity.

China remains a massive diabetes market (140M+ patients), and weekly dosing is a real competitive edge vs daily insulins. Novo's local manufacturing footprint and regulatory momentum in China continue to strengthen. Watch uptake closely — if reimbursement comes through, this could be meaningful volume growth beyond GLP-1 obesity tailwinds.

Still constructive on $NVO's pipeline depth and global reach.